Locations:
Search IconSearch
April 2, 2024/Neurosciences/Podcast

Diagnosis and Management of Cerebral Amyloid Angiopathy-Related Inflammation (Podcast)

New research sheds light on a potentially devastating condition that is reversible when properly managed

Cerebral amyloid angiopathy is a cerebrovascular disorder characterized by accumulation of amyloid proteins in small blood vessels of the brain and leptomeninges, leading to fragile vessel walls and subsequent brain bleeds. A subset of people with the disorder develop an inflammatory reaction to the amyloid deposition known as cerebral amyloid angiopathy-related inflammation (CAA-RI), which causes progressive cognitive decline.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“As devastating as CAA-RI can be — it can even lead to seizures and sometimes coma — it is still very treatable and reversible,” says Abbas Kharal, MD, a stroke neurologist and immunologist in the Cerebrovascular Center at Cleveland Clinic. “The inflammation is very reversible and treatable with steroids and other immunosuppressive agents.”

In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Kharal discusses the diagnosis and management of CAA-RI, delving into:

  • How cerebral amyloid angiopathy and CAA-RI present in patients
  • The overlap between Alzheimer’s disease and cerebral amyloid angiopathy
  • When and how often to image patients
  • Surgical interventions and medical therapies to treat CAA-RI
  • Research aimed at determining the prevalence of CAA-RI and improving clinical care

Click the podcast player above to listen to the 30-minute episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

This activity has been approved for AMA PRA Category 1 Credit™and ANCC contact hours. After listening to the podcast, you can claim your credit here.

Excerpt from the podcast

Podcast host Glen Stevens, DO, PhD: What percentage of people who have cerebral amyloid angiopathy will get the inflammation?

Dr. Kharal: That's an excellent question. And the answer is that we don’t know! That is what our research paper tried to explain. We talk about cerebral amyloid angiopathy-related inflammation as it comes to attention when patients present with rapid cognitive decline, seizures, headaches or other signs of edema. And we pick it up on imaging and conclude that the patient has either known cerebral amyloid angiopathy before, or a new diagnosis, and a pattern that fits with edema either vasogenic edema or T2 FLAIR hyperintensity in areas of cerebral microbleeds that is much more than what you’d expect from microbleeds alone. But I still don't think we understand the true prevalence, so our study tried to look at asymptomatic and symptomatic CAA-RI together.

Advertisement

There is a term that we put out in the literature, “radiological cerebral amyloid angiopathy-related inflammation.” It basically is cerebral amyloid angiopathy-related inflammation that radiographically meets criteria for CAA-RI that may not manifest symptomatically — may not present with the headaches or the cognitive decline or seizures yet — versus the clinico-radiographic CAA-RI, which is clinically manifesting and has radiographic evidence.

In our study we showed that CAA-RI was prevalent in about 10.8% of 511 patients with cerebral amyloid angiopathy that we reviewed. That percentage represents those who had at least radiological CAA-RI, some of whom also had clinical radiographic evidence as well. But if we looked specifically at the subgroup of patients with CAA with white matter disease of any type, the prevalence of CAA-RI was as high as 28%.

Advertisement

Related Articles

brain MRI showing inflammation related to cerebral amyloid angiopathy
November 29, 2023/Neurosciences/Cerebrovascular
Early Brain Inflammation Underappreciated in Cerebral Amyloid Angiopathy

Vigilant MRI evaluation needed for prompt care of potentially reversible inflammation, study finds

portrait of dr. demitre serletis against decorative background
December 2, 2024/Neurosciences/Podcast
SEEG in Epilepsy Surgery Evaluation: Current and Future Roles (Podcast)

Insights on how stereoelectroencephalography is continuing to improve seizure localization

William Clifton, MD, against a decorative background
November 4, 2024/Neurosciences/Podcast
Adult Idiopathic Scoliosis: Essentials of Diagnosis and Treatment (Podcast)

Early intervention yields the best outcomes, but surgery can benefit older patients as well

Creative illustration of a brain
October 16, 2024/Neurosciences/Podcast
Diagnosing Atypical Parkinsonian Disorders (Podcast)

Patient history plays a key role in identifying the condition

dr. daniel ontaneda against a decorative background
October 2, 2024/Neurosciences/Podcast
Takeaways From the New Diagnostic Criteria for Multiple Sclerosis (Podcast)

A co-author explains some of the key McDonald criteria revisions

Dr. Imad Najm against a decorative background
September 16, 2024/Neurosciences/Podcast
Temporal Lobe Epilepsy and the Potential of Gene Therapy (Podcast)

Investigational gene approaches offer hope for a therapeutically challenging condition

alison stout, DO, against a decorative backdrop
August 9, 2024/Neurosciences/Podcast
Evaluation and Interventional Treatment of Axial Lumbar Back Pain (Podcast)

This common condition remains tough to work up and diagnose, and treatment options are limited

Dr. Amy Kunchok against decorative background
July 16, 2024/Neurosciences/Podcast
What to Know About Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) (Podcast)

It’s time to get familiar with this emerging demyelinating disorder

Ad